Specifically, targeting bone-MM cell interactions via bone biology modulating factors such as DKK1 and RANKL is likely to trigger anti-MM effects but also improves bone disease thereby improving both patient survival as well as patient's quality of life. The gene discussed is TNFSF11; the disease is Miyoshi myopathy.